New pill shows promise for Hard-to-Treat blood cancers in japanese patients

NCT ID NCT03198650

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the cancer responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PART1: ADVANCED B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma mantle cell lymphoma neoplasm of mature B-cells

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PART1: ADVANCED B-CELL MALIGNANCIES PART2: R/RCLL AND R/RMCL PART3: UNTREATED CLL

Contacts and locations

Locations

Research Site

Chiba, 260-8717, Japan
Research Site

Chūōku, 104-0045, Japan
Research Site

Fukuoka, 812-8582, Japan
Research Site

Isehara-shi, 259-1193, Japan
Research Site

Izumo-shi, 693-8501, Japan
Research Site

Matsuyama, 791-0280, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8520, Japan
Research Site

Okayama, 700-8558, Japan
Research Site

Sapporo, 060-8638, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Suita-shi, 565-0871, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.